[SCHEDULE 13G/A] PLUS THERAPEUTICS, Inc. SEC Filing

Rhea-AI Filing Summary

Schedule 13G/A (Amendment No. 1) filing for Plus Therapeutics, Inc. (NASDAQ: PSTV) discloses that The Hewlett Fund LP no longer holds any beneficial ownership in the company’s common stock.

Key facts:

• Date of event: 24 June 2025
• Reporting person: The Hewlett Fund LP (a New York limited partnership)
• Shares beneficially owned: 0.00
• Percent of class: 0%
• Voting & dispositive power: 0 shares sole or shared
• Reason for filing: Ownership has fallen to (or remains) 5 percent or less of outstanding common stock, triggering a final amendment under Rule 13d-2.

This amendment replaces an earlier Schedule 13G in which the same fund reported an ownership position exceeding the 5 % reporting threshold. By certifying zero shares, The Hewlett Fund LP confirms that it has fully exited its previously disclosed stake and no longer seeks to influence control of Plus Therapeutics. Apart from this ownership update, the filing contains no financial performance data, strategic commentary or transactional details.

Positive

• None.

Negative

• The Hewlett Fund LP now reports 0% ownership, signalling a complete exit and potential loss of institutional support for PSTV.

Insights

Financial Analyst

TL;DR: Large holder exits PSTV, eliminating prior >5 % stake; modest negative signal.

The Hewlett Fund LP’s complete divestiture reduces institutional ownership and may slightly weaken the demand side of PSTV’s float. Because the fund had previously crossed the 5 % threshold, its withdrawal suggests it no longer sees a compelling near-term upside. While not dilutive, the absence of a committed shareholder can diminish market confidence and increase share-price volatility, especially for a micro-cap biotech reliant on supportive capital bases. No new strategic investors are identified to offset this exit, so the filing leans negative for sentiment rather than fundamentals.

Corporate Governance Specialist

TL;DR: Governance neutral — fund’s sale removes potential influence over PSTV’s decisions.

With ownership at 0 %, The Hewlett Fund LP relinquishes any voting or activist leverage. This simplifies PSTV’s shareholder map and lowers the risk of coordinated control campaigns flagged under 13D rules. From a governance standpoint, management faces fewer constraints from this particular investor but might need to broaden investor outreach to maintain diversified support. The event is formally material only because it crosses the statutory 5 % threshold; operational impact is limited.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

PLUS THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK, $0.001 PAR VALUE PER SHARE

(Title of Class of Securities)

72941H509

(CUSIP Number)

06/24/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 72941H509

1

Names of Reporting Persons

The Hewlett Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PLUS THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 2710 Reed Rd., Suite 160, Houston, TX 77051
Item 2.
(a)	Name of person filing: The Hewlett Fund LP
(b)	Address or principal business office or, if none, residence: 100 Merrick Road, Suite 400W, Rockville Centre, NY 11570
(c)	Citizenship: New York
(d)	Title of class of securities: COMMON STOCK, $0.001 PAR VALUE PER SHARE
(e)	CUSIP No.: 72941H509
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0.00
(b)	Percent of class: 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Hewlett Fund LP

Signature:	/s/ Martin Chopp
Name/Title:	Martin Chopp, General Partner
Date:	06/25/2025

FAQ

Why did The Hewlett Fund LP file a Schedule 13G/A for PSTV?

Because its beneficial ownership fell to 5 % or less, requiring an amendment to update holdings to 0 shares.

How many Plus Therapeutics (PSTV) shares does The Hewlett Fund LP currently own?

The filing states 0.00 shares, representing 0 % of the outstanding common stock.

What is the effective date of The Hewlett Fund LP's ownership change?

The event date triggering the filing is June 24, 2025.

Does the filing indicate any voting or dispositive power retained by The Hewlett Fund LP?

No. The fund reports 0 shares with both sole and shared voting or dispositive power.

Is this Schedule 13G/A likely to impact Plus Therapeutics’ control structure?

With the fund’s ownership at 0 %, it no longer has influence over PSTV’s governance, reducing potential control considerations.